Article in Nature chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Darryl A WesenerEdison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO, USA. wesener.1@osu.edu.ORCID 0000-0002-8132-7018
Zachary W BellerEdison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO, USA.
Megan F HillDepartment of Microbiology, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-6128-6338
Han YuanKaleido Biosciences, Lexington, MA, USA.
David B BelangerKaleido Biosciences, Lexington, MA, USA.
Cheryl FrankfaterBiomedical Mass Spectrometry Resource, Washington University School of Medicine, St. Louis, MO, USA.
Nicolas TerraponArchitecture et Fonction des Macromolecules Biologiques, CNRS, Aix-Marseille University, Marseille, France.ORCID 0000-0002-3693-6017
Bernard HenrissatDepartment of Biotechnology and Biomedicine (DTU Bioengineering), Technical University of Denmark, Lyngby, Denmark.ORCID 0000-0002-3434-8588
Dmitry A RodionovInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-0939-390X
Semen A LeynInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-9886-9120
Andrei OstermanInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID 0000-0002-3810-9824
Johan E T van Hylckama VliegKaleido Biosciences, Lexington, MA, USA.
Jeffrey I GordonEdison Family Center for Genome Sciences and Systems Biology, Washington University School of Medicine, St. Louis, MO, USA. jgordon@wustl.edu.ORCID 0000-0001-8304-3548
Funding
NATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8M
Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 1999 to 2026
$30.2M
WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI James Alexander Fitzpatrick · 2013 to 2026
$27.1M
REGULATION OF GENE EXPRESSION - SMALL INTESTINER01DK030292 · NIDDK · WASHINGTON UNIVERSITY · PI JEFFREY I GORDON, ANDREI L OSTERMAN · 1986 to 2026
$6.5M
GUT MICROBIOTA AND OBESITY: STUDIES IN GNOTOBIOTIC MICER01DK070977 · NIDDK · WASHINGTON UNIVERSITY · PI GORDON, JEFFREY I, HETTICH, ROBERT L. · 2005 to 2020
$6.3M
REGULATION OF GENE EXPRESSION IN THE SMALL INTESTINER37DK030292 · NIDDK · WASHINGTON UNIVERSITY · PI GORDON, JEFFREY I · 1993 to 2015
$4.0M
A Biomedical Mass Spectrometry Resource: Ongoing Driving Biomedical ProjectsR24GM136766 · NIGMS · WASHINGTON UNIVERSITY · PI GROSS, MICHAEL L · 2020 to 2022
$2.3M
Human gut bacterial cell surface polysaccharides as a microbial nutrient source and target of immunoregulatory proteins shape gut microbiota structure and functionR00AT011374 · NCCIH · OHIO STATE UNIVERSITY · PI WESENER, DARRYL A · 2023 to 2025
$707k
The role and fate of Mtb storage lipids LCTAG and MWER21AI144658 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI PURDY, GEORGIANA E. · 2020 to 2021
$438k
Human gut bacterial cell surface polysaccharides as a microbial nutrient source and target of immunoregulatory proteins shape gut microbiota structure and functionK99AT011374 · NCCIH · WASHINGTON UNIVERSITY · PI WESENER, DARRYL A · 2021 to 2022
$217k
Impact of Gut Bacterial Interactions on the Response to Fiber-Based PrebioticsF30DK123838 · NIDDK · WASHINGTON UNIVERSITY · PI BELLER, ZACHARY WALTER · 2020 to 2022
$127k
Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation) DRG-2303-17NCCIH NIH HHS K99 AT011374NCCIH NIH HHS R00 AT011374NIAID NIH HHS R21 AI144658NIDDK NIH HHS F30 DK123838NIDDK NIH HHS P30 DK020579NIDDK NIH HHS P30 DK056341NIDDK NIH HHS R01 DK030292NIDDK NIH HHS R01 DK070977NIDDK NIH HHS R37 DK030292NIGMS NIH HHS R24 GM136766NIGMS NIH HHS T32 GM007200U.S. Department of Health & Human Services | NIH | Center for Scientific Review (NIH Center for Scientific Review) DK30292U.S. Department of Health & Human Services | NIH | National Center for Complementary and Integrative Health (NCCIH) AT011374U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) DK70977
6 · The paper itself
Abstract
Synthetic glycans (SGs) containing glycosidic linkages and structures not identified in nature offer a means for deliberately altering microbial community properties. Here pools of SG oligosaccharides were generated via polymerization of monosaccharides and screened for their ability to increase saccharolytic Bacteroides in ex vivo cultures of human fecal samples. A lead SG preparation was orally administered to gnotobiotic mice harboring a consortium of 56 cultured, phylogenetically diverse human gut bacteria and fed a Western diet. The abundances of 3 of 15 Bacteroides strains increased, most prominently B. intestinalis. Underlying mechanisms were characterized by analyzing in vivo expression of the carbohydrate utilization machinery, using retrievable microscopic paramagnetic particles with bound SG oligosaccharides and assaying SG degradation by individual purified B. intestinalis glycoside hydrolases. The results reveal that SGs can selectively co-opt carbohydrate utilization machinery in different human gut Bacteroides and demonstrate a means for identifying artificial carbohydrate structures for targeted bacterial manipulation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
In vivo manipulation of human gut Bacteroides fitness by abiotic oligosaccharides. · full record | Socratic